Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 1,045 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| BioRestorative Therapies Inc | BRTX | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.46 | 07:04:17 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.46 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 10 | 1,045 | - | 1.20 - 7.13 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 07:03:13 | 10 | US$ 1.50 | USD |
BioRestorative Therapies Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 6.87M | 4.71M | - | 146k | -14.42M | -3.06 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
BioRestorative Therapies News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BRTX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.24 | 1.55 | 1.21 | 1.42 | 3,682,837 | 0.22 | 17.74% |
| 1 Month | 1.33 | 1.65 | 1.21 | 1.38 | 1,549,131 | 0.13 | 9.77% |
| 3 Months | 1.36 | 1.65 | 1.21 | 1.38 | 600,165 | 0.10 | 7.35% |
| 6 Months | 1.84 | 3.6699 | 1.20 | 2.06 | 493,199 | -0.38 | -20.65% |
| 1 Year | 4.08 | 7.13 | 1.20 | 2.21 | 270,326 | -2.62 | -64.22% |
| 3 Years | 8.90 | 8.90 | 1.20 | 3.27 | 225,720 | -7.44 | -83.60% |
| 5 Years | 8.90 | 8.90 | 1.20 | 3.27 | 225,720 | -7.44 | -83.60% |
BioRestorative Therapies Description
| BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue. |
